New combo therapy shows promise for tough liver cancer cases
NCT ID NCT06881446
First seen May 15, 2026 · Last updated May 22, 2026 · Updated 2 times
Summary
This study looked at over 2,600 people with advanced liver cancer that had invaded major blood vessels. Researchers compared standard immunotherapy plus anti-angiogenesis drugs with and without a procedure called TACE (which delivers chemo directly to the liver). The goal was to see which approach helped people live longer and kept tumors from growing. Results focused on overall survival and progression-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.